Advertisement

Distinct prognostic values of Annexin family members expression in acute myeloid leukemia

  • Y. Niu
  • X. Yang
  • Y. Chen
  • X. Jin
  • Y. Xie
  • Y. Tang
  • L. Li
  • S. Liu
  • Y. Guo
  • X. Li
  • L. Duan
  • H. WangEmail author
Research Article
  • 25 Downloads

Abstract

Background

Annexin family consist of 12 members, many of them are frequently dysregulated in human cancers. However, the diagnosis and prognosis of Annexin family expression in acute myeloid leukemia (AML) remain elusive. The aim of the present study was to assess the prognostic value of Annexin expressions in adult and pediatric AML.

Methods

GenomicScape tool was used to assess the prognostic value of the expressions of Annexin family members in a cohort of 162 adult AML patients. Quantitative reverse transcript real-time PCR (QRT-PCR) was performed to detect the ANXA2 expression level in the bone marrow-derived mononuclear cells (BMMCs) obtained from 101 pediatric AML patients and 30 controls.

Results

The results demonstrated that high mRNA expressions of ANXA2, ANXA6, and ANXA7 were significantly associated with worse prognosis, while ANXA5 was correlated with better prognosis in adult AML. QRT-PCR analysis showed that ANXA2 expression was dramatically downregulated in BMMCs of pediatric AML patients compared to controls (p < 0.0001). ROC analysis demonstrated that ANXA2 could efficiently differentiate pediatric AML patients from controls (AUC 0.872, p < 0.0001). Likewise, ANXA2 was significantly lower in AML patients with poor-risk karyotype (p = 0.048). Also, the level of ANXA2 trended to decrease in AML patients who had not achieving complete remission. Moreover, patients with lower expression of ANXA2 had higher death rate (p = 0.042) and shorter overall survival (HR 0.55, p = 0.042). Thus, these findings suggest that ANXA2 exerts poor prognostic effect on adult AML but favorable prognostic effect on pediatric AML.

Conclusions

Collectively, Annexin family members exert distinct prognostic roles in AML, and ANXA2 can be used as a biological marker for diagnosis and prognosis of pediatric AML.

Keywords

Acute myeloid leukemia Prognostic biomarker Annexin family ANXA2 

Notes

Author contributions

Conceived and designed the experiment: HW, YN; Performed the experiments: XY, YC, XJ, LL; Patients sample preparation: LZ, YT, SL, YG.

Funding

This work was supported by National Natural Science Foundation of China (Grant nos. 81701554 and 81702099), and Natural Science Foundation of Henan Province (Grant no. 162300410213).

Compliance with ethical standards

Conflict of interest

No potential conflicts of interests were disclosed.

Ethical approval

The study was approved by the Scientific Committee on Research and Ethics of the Children Hospital of Soochow University.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Supplementary material

12094_2019_2045_MOESM1_ESM.tif (5.1 mb)
Supplementary material 1 (TIFF 5267 kb)
12094_2019_2045_MOESM2_ESM.tif (2.5 mb)
Supplementary material 2 (TIFF 2530 kb)
12094_2019_2045_MOESM3_ESM.tif (6 mb)
Supplementary material 3 (TIFF 6143 kb)
12094_2019_2045_MOESM4_ESM.tif (2.9 mb)
Supplementary material 4 (TIFF 2994 kb)

References

  1. 1.
    Dombret H, Gardin C. An update of current treatments for adult acute myeloid leukemia. Blood. 2016;127(1):53–61.  https://doi.org/10.1182/blood-2015-08-604520.CrossRefGoogle Scholar
  2. 2.
    Grimwade D, Ivey A, Huntly BJ. Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance. Blood. 2016;127(1):29–41.  https://doi.org/10.1182/blood-2015-07-604496.CrossRefGoogle Scholar
  3. 3.
    Gerke V, Creutz CE, Moss SE. Annexins: linking Ca2+ signalling to membrane dynamics. Nat Rev Mol Cell Biol. 2005;6(6):449–61.  https://doi.org/10.1038/nrm1661.CrossRefGoogle Scholar
  4. 4.
    Grewal T, Enrich C. Annexins–modulators of EGF receptor signalling and trafficking. Cell Signal. 2009;21(6):847–58.CrossRefGoogle Scholar
  5. 5.
    Gerke V, Moss SE. Annexins: from structure to function. Physiol Rev. 2002;82(2):331–71.  https://doi.org/10.1152/physrev.00030.2001.CrossRefGoogle Scholar
  6. 6.
    Tu Y, Johnstone CN, Stewart AG. Annexin A1 influences in breast cancer: controversies on contributions to tumour, host and immunoediting processes. Pharmacol Res. 2017;119:278–88.  https://doi.org/10.1016/j.phrs.2017.02.011.CrossRefGoogle Scholar
  7. 7.
    Biaoxue R, Xiguang C, Hua L, Tian F, Wenlong G. Increased level of annexin A1 in bronchoalveolar lavage fluid as a potential diagnostic indicator for lung cancer. Int J Biol Mark. 2017;32(1):e132–40.  https://doi.org/10.5301/jbm.5000243.CrossRefGoogle Scholar
  8. 8.
    Rentero C, Blanco-Munoz P, Meneses-Salas E, Grewal T, Enrich C. Annexins-coordinators of cholesterol homeostasis in endocytic pathways. Int J Mol Sci. 2018.  https://doi.org/10.3390/ijms19051444.Google Scholar
  9. 9.
    Biaoxue R, Xiguang C, Shuanying Y. Annexin A1 in malignant tumors: current opinions and controversies. Int J Biol Mark. 2014;29(1):e8–20.  https://doi.org/10.5301/jbm.5000046.CrossRefGoogle Scholar
  10. 10.
    Yan X, Yin J, Yao H, Mao N, Yang Y, Pan L. Increased expression of annexin A3 is a mechanism of platinum resistance in ovarian cancer. Can Res. 2010;70(4):1616–24.  https://doi.org/10.1158/0008-5472.CAN-09-3215.CrossRefGoogle Scholar
  11. 11.
    Lin LL, Huang HC, Juan HF. Revealing the molecular mechanism of gastric cancer marker annexin A4 in cancer cell proliferation using exon arrays. PLoS One. 2012;7(9):e44615.  https://doi.org/10.1371/journal.pone.0044615.CrossRefGoogle Scholar
  12. 12.
    Zheng MD, Wang ND, Li XL, Yan J, Tang JH, Zhao XH, et al. Toosendanin mediates cisplatin sensitization through targeting Annexin A4/ATP7A in non-small cell lung cancer cells. J Nat Med. 2018.  https://doi.org/10.1007/s11418-018-1211-0.Google Scholar
  13. 13.
    Haiman CA, Han Y, Feng Y, Xia L, Hsu C, Sheng X, et al. Genome-wide testing of putative functional exonic variants in relationship with breast and prostate cancer risk in a multiethnic population. PLoS Genet. 2013;9(3):e1003419.  https://doi.org/10.1371/journal.pgen.1003419.CrossRefGoogle Scholar
  14. 14.
    Wei B, Guo C, Liu S, Sun MZ. Annexin A4 and cancer. Clinica Chimica Acta Int J Clin Chem. 2015;447:72–8.  https://doi.org/10.1016/j.cca.2015.05.016.CrossRefGoogle Scholar
  15. 15.
    D’Souza S, Kurihara N, Shiozawa Y, Joseph J, Taichman R, Galson DL, et al. Annexin II interactions with the annexin II receptor enhance multiple myeloma cell adhesion and growth in the bone marrow microenvironment. Blood. 2012;119(8):1888–96.  https://doi.org/10.1182/blood-2011-11-393348.CrossRefGoogle Scholar
  16. 16.
    O’Connell PA, Madureira PA, Berman JN, Liwski RS, Waisman DM. Regulation of S100A10 by the PML-RAR-alpha oncoprotein. Blood. 2011;117(15):4095–105.  https://doi.org/10.1182/blood-2010-07-298851.CrossRefGoogle Scholar
  17. 17.
    Spijkers-Hagelstein JA, Mimoso Pinhancos S, Schneider P, Pieters R, Stam RW. Src kinase-induced phosphorylation of annexin A2 mediates glucocorticoid resistance in MLL-rearranged infant acute lymphoblastic leukemia. Leukemia. 2013;27(5):1063–71.  https://doi.org/10.1038/leu.2012.372.CrossRefGoogle Scholar
  18. 18.
    Chiang Y, Davis RG, Vishwanatha JK. Altered expression of annexin II in human B-cell lymphoma cell lines. Biochem Biophys Acta. 1996;1313(3):295–301.CrossRefGoogle Scholar
  19. 19.
    Weston-Bell NJ, Hendriks D, Sugiyarto G, Bos NA, Kluin-Nelemans HC, Forconi F, et al. Hairy cell leukemia cell lines expressing annexin A1 and displaying B-cell receptor signals characteristic of primary tumor cells lack the signature BRAF mutation to reveal unrepresentative origins. Leukemia. 2013;27(1):241–5.  https://doi.org/10.1038/leu.2012.163.CrossRefGoogle Scholar
  20. 20.
    Handschuh L, Kazmierczak M, Milewski MC, Goralski M, Luczak M, Wojtaszewska M, et al. Gene expression profiling of acute myeloid leukemia samples from adult patients with AML-M1 and -M2 through boutique microarrays, real-time PCR and droplet digital PCR. Int J Oncol. 2018;52(3):656–78.  https://doi.org/10.3892/ijo.2017.4233.Google Scholar
  21. 21.
    Tressler RJ, Yeatman T, Nicolson GL. Extracellular annexin VI expression is associated with divalent cation-dependent endothelial cell adhesion of metastatic RAW117 large-cell lymphoma cells. Exp Cell Res. 1994;215(2):395–400.  https://doi.org/10.1006/excr.1994.1358.CrossRefGoogle Scholar
  22. 22.
    Zhang LY, Jiang M, Li X, Shen F, Jia R, Ruan CG. Expression of annexin II in patients with hematologic malignancies. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2009;17(3):529–32.Google Scholar
  23. 23.
    Kassambara A, Reme T, Jourdan M, Fest T, Hose D, Tarte K, et al. GenomicScape: an easy-to-use web tool for gene expression data analysis. Application to investigate the molecular events in the differentiation of B cells into plasma cells. PLoS Comput Biol. 2015;11(1):e1004077.  https://doi.org/10.1371/journal.pcbi.1004077.CrossRefGoogle Scholar
  24. 24.
    Basso K, Liso A, Tiacci E, Benedetti R, Pulsoni A, Foa R, et al. Gene expression profiling of hairy cell leukemia reveals a phenotype related to memory B cells with altered expression of chemokine and adhesion receptors. J Exp Med. 2004;199(1):59–68.  https://doi.org/10.1084/jem.20031175.CrossRefGoogle Scholar
  25. 25.
    Sadik W, Coupland S, Thachil J. Hairy cell leukaemia, negative for conventional cell markers, diagnosed using antibodies to annexin A1 and T-bet. Br J Haematol. 2010;151(3):207.  https://doi.org/10.1111/j.1365-2141.2010.08359.x.CrossRefGoogle Scholar
  26. 26.
    Szczepanek J, Laskowska J, Lewandowska-Bieniek J, Tretyn A, Styczynski J. Array-based genomic and transcriptomic profiling in pediatric acute leukemias in search of genes responsible for cyclophosphamide resistance. Blood. 2014;124(21):3802.Google Scholar
  27. 27.
    Proto-Siqueira R, Panepucci RA, Careta FP, Lee A, Clear A, Morris K, Owen C, Rizzatti EG, Silva WA Jr, Falcão RP, Zago MA, Gribben JG. SAGE analysis demonstrates increased expression of TOSO contributing to Fas-mediated resistance in CLL. Blood. 2008;112(2):394–7.  https://doi.org/10.1182/blood-2007-11-124065.CrossRefGoogle Scholar
  28. 28.
    Lindberg ML, Haag P, Moshfegh A, Kanter L, Bjorkholm M, Lewensohn R, Kristina V, Stenke L. Gene expression analyses at time of diagnosis indicate biomarkers predictive of therapeutic response in acute myeloid leukemia. Blood. 2013;122(21):2619.Google Scholar
  29. 29.
    Chitteti BR, Poteat B, Wang M, Liu Y, Srour EF. Genetic and proteomic analysis of functionally distinct human hematopoietic stem cells from bone marrow, mobilized peripheral blood, and cord blood. Blood. 2008;112(11):1324.Google Scholar
  30. 30.
    Hayhoe RP, Kamal AM, Solito E, Flower RJ, Cooper D, Perretti M. Annexin 1 and its bioactive peptide inhibit neutrophil-endothelium interactions under flow: indication of distinct receptor involvement. Blood. 2006;107(5):2123–30.  https://doi.org/10.1182/blood-2005-08-3099.CrossRefGoogle Scholar
  31. 31.
    Tsai WH, Chien HY, Shih CH, Lai SL, Li IT, Hsu SC, et al. Annexin A1 mediates the anti-inflammatory effects during the granulocytic differentiation process in all-trans retinoic acid-treated acute promyelocytic leukemic cells. J Cell Physiol. 2012;227(11):3661–9.  https://doi.org/10.1002/jcp.24073.CrossRefGoogle Scholar
  32. 32.
    Bao H, Jiang M, Zhu M, Sheng F, Ruan J, Ruan C. Overexpression of Annexin II affects the proliferation, apoptosis, invasion and production of proangiogenic factors in multiple myeloma. Int J Hematol. 2009;90(2):177–85.  https://doi.org/10.1007/s12185-009-0356-8.CrossRefGoogle Scholar
  33. 33.
    Seckinger A, Meissner T, Moreaux J, Depeweg D, Hillengass J, Hose K, et al. Clinical and prognostic role of annexin A2 in multiple myeloma. Blood. 2012;120(5):1087–94.  https://doi.org/10.1182/blood-2012-03-415588.CrossRefGoogle Scholar
  34. 34.
    Tumino M, Accordi B, Sciro M, Milani G, Tognazzo F, Giordan M, Kronnie TT, Basso G, Nigro LL. Expression of Annexin 2 in pediatric B-acute lymphoblastic leukemia: a marker of aggressiveness and a potential therapeutic target. Blood. 2009;114(22):2605.Google Scholar
  35. 35.
    Chang KS, Wang G, Freireich EJ, Daly M, Naylor SL, Trujillo JM, et al. Specific expression of the annexin VIII gene in acute promyelocytic leukemia. Blood. 1992;79(7):1802–10.Google Scholar
  36. 36.
    Payton JE, Grieselhuber NR, Chang LW, Murakami MA, Yuan W, Link DC, Nagarajan R, Watson MA, Ley TJ. The expression signature of M3 AML suggests direct and indirect effects of PML-RARA on target genes. Blood. 2007;110(11):719.Google Scholar
  37. 37.
    Sarkar A, Yang P, Fan YH, Mu ZM, Hauptmann R, Adolf GR, et al. Regulation of the expression of annexin VIII in acute promyelocytic leukemia. Blood. 1994;84(1):279–86.Google Scholar
  38. 38.
    Hata H, Tatemichi M, Nakadate T. Involvement of annexin A8 in the properties of pancreatic cancer. Mol Carcinog. 2014;53(3):181–91.  https://doi.org/10.1002/mc.21961.CrossRefGoogle Scholar
  39. 39.
    Chao A, Wang TH, Lee YS, Hsueh S, Chao AS, Chang TC, et al. Molecular characterization of adenocarcinoma and squamous carcinoma of the uterine cervix using microarray analysis of gene expression. Int J Cancer. 2006;119(1):91–8.  https://doi.org/10.1002/ijc.21813.CrossRefGoogle Scholar
  40. 40.
    Oka R, Nakashiro K, Goda H, Iwamoto K, Tokuzen N, Hamakawa H. Annexin A8 is a novel molecular marker for detecting lymph node metastasis in oral squamous cell carcinoma. Oncotarget. 2016;7(4):4882–9.  https://doi.org/10.18632/oncotarget.6639.CrossRefGoogle Scholar
  41. 41.
    Rossetti S, Bshara W, Reiners JA, Corlazzoli F, Miller A, Sacchi N. Harnessing 3D models of mammary epithelial morphogenesis: an off the beaten path approach to identify candidate biomarkers of early stage breast cancer. Cancer Lett. 2016;380(2):375–83.  https://doi.org/10.1016/j.canlet.2016.07.003.CrossRefGoogle Scholar

Copyright information

© Federación de Sociedades Españolas de Oncología (FESEO) 2019

Authors and Affiliations

  1. 1.Henan Collaborative Innovation Center of Molecular Diagnosis and Laboratory Medicine, School of Laboratory MedicineXinxiang Medical UniversityXinxiangPeople’s Republic of China
  2. 2.Henan Key Laboratory of Immunology and Targeted TherapyXinxiang Medical UniversityXinxiangPeople’s Republic of China
  3. 3.Laboratory of HematologyThe First Affiliated Hospital of Xinxiang Medical UniversityWeihuiPeople’s Republic of China

Personalised recommendations